KLRK1 and Miyoshi myopathy: The same group’s earlier work presented at ASH 2018 confirmed efficient gene transfer, stable CAR expression, and selective killing of BCMA-positive and BCMA-negative MM populations, highlighting the advantage of NKG2D CARs in addressing clonal diversity [23].